This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Dennis, PhD
Fellow at Denali Therapeutics

Profile

Building on 35 years of experience in protein and antibody engineering while a Principal Scientist at Genentech, Mark is currently a Fellow at Denali Therapeutics providing strategic direction and guidance for the development of protein therapeutics targeting neurological diseases. While at Genentech, Mark developed a practical method to deliver biotherapeutics across the blood-brain barrier, established that association with albumin could increase the serum half-life of biotherapeutics and was a key member of teams establishing early Antibody-drug conjugate (ADC) and T-cell Dependent
Bispecific (TDC) technologies for oncology. Mark has authored over 60 papers and contributed to over 30 granted patents.

Agenda Sessions

  • Enzyme Transport Vehicle (ETV): A Novel Brain Delivery Platform for Enzyme Replacement Therapies

    08:30